NCT06530914View on ClinicalTrials.gov

A Phase II Study of MRG003 Injection Combined With Pucotenlimab Injection ± Cisplatin Injection in the Neoadjuvant Treatment Locally Advanced EGFR-positive Head and Neck Squamous Cell Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions
DRUG

MRG003 combined with Pucotenlimab

Both interventions all drugs intravenous infusion, D1, once every 3 weeks, a total of 3 cycles.

DRUG

MRG003 combined with Pucotenlimab+Cisplatin

All interventions all drugs intravenous infusion, once every 3 weeks, a total of 3 cycles.

All Listed Sponsors
lead

Lei Liu

OTHER